Your browser doesn't support javascript.
loading
New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy.
Poli, Giulio; Di Stefano, Miriana; Estevez, Joan Arias; Minutolo, Filippo; Granchi, Carlotta; Giordano, Antonio; Parisi, Salvatore; Mauceri, Matteo; Canzonieri, Vincenzo; Macchia, Marco; Caligiuri, Isabella; Tuccinardi, Tiziano; Rizzolio, Flavio.
Afiliação
  • Poli G; Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Di Stefano M; Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Estevez JA; Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Minutolo F; Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Granchi C; Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Giordano A; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.
  • Parisi S; Pathology Unit, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
  • Mauceri M; Pathology Unit, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
  • Canzonieri V; Department of Molecular Science and Nanosystems, Ca' Foscari University of Venezia, Venezia-Mestre, Italy.
  • Macchia M; Pathology Unit, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
  • Caligiuri I; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
  • Tuccinardi T; Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Rizzolio F; Pathology Unit, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
J Enzyme Inhib Med Chem ; 37(1): 145-150, 2022 Dec.
Article em En | MEDLINE | ID: mdl-34894990
ABSTRACT
PIN1 is considered as a therapeutic target for a wide variety of tumours. However, most of known inhibitors are devoid of cellular activity despite their good enzyme inhibitory profile. Hence, the lack of effective compounds for the clinic makes the identification of novel PIN1 inhibitors a hot topic in the medicinal chemistry field. In this work, we reported a virtual screening study for the identification of new promising PIN1 inhibitors. A receptor-based procedure was applied to screen different chemical databases of commercial compounds. Based on the whole workflow, two compounds were selected and biologically evaluated. Both ligands, compounds VS1 and VS2, showed a good enzyme inhibitory activity and VS2 also demonstrated a promising antitumoral activity in ovarian cancer cells. These results confirmed the reliability of our in silico protocol and provided a structurally novel ligand as a valuable starting point for the development of new PIN1 inhibitors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores Enzimáticos / Peptidilprolil Isomerase de Interação com NIMA / Antineoplásicos Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores Enzimáticos / Peptidilprolil Isomerase de Interação com NIMA / Antineoplásicos Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article